VSTM · Verastem, Inc. · Stock research

Current Thesis

The July read on this name was that an accelerating KRAS science narrative sat on top of a tape that would not confirm it — pipeline optionality near cash value, a data catalyst with no date, and a financing decision on the clock. Three of those four conditions changed inside four weeks. The 2026-08-06 Q2 print delivered net product revenue of $25.1M against $23.093M consensus and a GAAP loss of $0.35 per share against a $(0.43) estimate; the company put the previously undated VS-7375 update in October 2026; and a non-dilutive royalty financing with Oberland Capital — up to $75M, $50M funding at closing on 2026-08-28 — pushed guided runway from H1 2027 to into H2 2027 without an equity raise. Price moved from $5.53 at the 2026-07-12 close to $6.74 on 2026-08-07, and RSI(14) sits at 68.1. What an investor is buying now is a commercial LGSOC franchise that management expects to be self-sustaining by end-2026 wrapped around a single dated binary: preliminary Phase 2 response rates for oral KRAS G12D inhibitor VS-7375 across pancreatic, lung and colorectal cancer, roughly 20 patients per tumor type, in October. The narrative leg is confirmation that the commercial base can fund the KRAS G12D land-grab — but the readout that reprices it is roughly two months out, and the intervening window is thin.

Bullish and bearish views on Verastem, Inc.

The model's bull view on Verastem, Inc. (VSTM), in brief: Q2 2026 (reported 2026-08-06): total revenue $40.1M versus $2.1M in Q2 2025; AVMAPKI FAKZYNJA CO-PACK net product revenue $25.1M, ahead of the $23.093M consensus; GAAP net loss $34.7M, or $0.35 per share, against a $(0.43) estimate. The bear view: Targets were cut into the rally, not raised. Both cases follow in full.

Bull Case

• Q2 2026 (reported 2026-08-06): total revenue $40.1M versus $2.1M in Q2 2025; AVMAPKI FAKZYNJA CO-PACK net product revenue $25.1M, ahead of the $23.093M consensus; GAAP net loss $34.7M, or $0.35 per share, against a $(0.43) estimate.
• The catalyst gap closed. Updated VS-7375 clinical data across PDAC, NSCLC and CRC — response rates in approximately 20 patients per tumor type — is guided to October 2026, replacing the "second half 2026" language that left July with nothing to trade against.
• Three registration-directed Phase 2 trials are dosing inside six weeks: TARGET-D 201 (2L metastatic PDAC) first patient 2026-06-16, TARGET-D 202 (2L/3L NSCLC) 2026-07-22, TARGET-D 203 (metastatic CRC) 2026-07-28. Phase 2 enrollment completion is targeted by end-2026, an FDA meeting on Phase 3 before year-end 2026, and Phase 3 enrollment initiation in H1 2027.
• Financing came non-dilutive. Cash and investments were $136.4M at 2026-06-30; pro forma $201.4M including the Oberland facility and a $15M COPIKTRA sales milestone. The optional second Oberland tranche of up to $25M is available if quarterly worldwide net sales of the co-pack reach $40M before 2027-05-15.
• Sell-side targets remain multiples of the 2026-08-07 close of $6.74 even after two trims: Guggenheim Buy, target cut to $12 on 2026-08-07; RBC Outperform, target cut to $14 on 2026-07-07; HC Wainwright and BTIG both at $18, reiterated 2026-06-24.

Bear Case

• Targets were cut into the rally, not raised. RBC took $14 on 2026-07-07 and Guggenheim took $12 on 2026-08-07 — ratings held, numbers came down, while the stock advanced.
• The October update is preliminary Phase 2 data at roughly 20 patients per tumor type. Cohorts that size support directional reads, not cross-trial superiority claims against Revolution Medicines' RMC-9805 or the Astellas and BMS programs chasing the same target.
• The $25M contingent Oberland tranche requires quarterly co-pack net sales of $40M before 2027-05-15, against $25.1M booked in Q2 2026. That is a meaningful step-up on a rare-indication launch.
• The royalty structure is non-dilutive but encumbers the commercial asset's revenue stream, and Phase 3 enrollment is targeted to begin H1 2027 — spend that lands before runway guided "into the second half of 2027" is exhausted.
• Accelerated-approval risk is unresolved for a year: RAMP 301 confirmatory topline is guided to mid-2027, sitting underneath the entire commercial floor.
• Despite the improved print, price is 37.4% below the 52-week high of $10.77 as of 2026-08-07. The move off July lows has not reclaimed the June highs.

Setup & Price Structure

• Last completed daily close $6.74 (2026-08-07) against $5.53 on 2026-07-12. Three-month return +37.8%. RSI(14) 68.1. Distance from the 52-week high of $10.77: -37.4%.
• Life-cycle: ACCELERATING, and dated by three events inside six weeks — the 2026-07-28 CRC dosing announcement, the 2026-08-06 revenue and EPS beat, and the 2026-08-07 Guggenheim note. Participation is expanding off a July base rather than fading out of a mainstream top; the name is not near its own high, which is inconsistent with a saturated setup.
• Crowding and positioning observables, stated as observables: RSI(14) at 68.1 is in the upper band but not extreme; a +37.8% three-month advance means fresh entries chase a move already made; the earnings print is behind (2026-08-06), so no company-reported number lands inside 30 days to either confirm or break the ramp; the financing question was answered with royalty capital rather than an equity issuance into strength, removing the specific dilution overhang flagged in the prior note; two banks lowered targets while maintaining Buy-equivalent ratings in the last five weeks.
• The structure that matters is the July shelf near the $5.53 close of 2026-07-12 and the post-print advance above it. The gap between $6.74 and the $10.77 high is unfilled overhead supply from the June data spikes.

Catalyst Calendar (next 30 days)

• 2026-08-28 — Oberland Capital royalty financing closing, $50M funding. Converts the pro forma $201.4M cash figure into actual cash and validates the runway-into-H2-2027 guidance.
• ~2026-09-08 (est.) — no company-scheduled event; the window between the Q2 print and October data carries conference abstract drops and competitor KRAS G12D disclosures as the realistic sources of headline risk.
• Beyond the window, dated for reference: ~2026-10-31 (est.) VS-7375 TARGET-D response-rate update across PDAC/NSCLC/CRC; ~2026-11-05 (est.) Q3 2026 print on the 2026-05-07 / 2026-08-06 reporting cadence; ~2026-12-31 (est.) FDA meeting on Phase 3 design and targeted Phase 2 enrollment completion.

What Would Change Our Mind

The structure that has to hold is the July base the post-print advance was built on. A weekly close below $5.50 erases the entire move off the 2026-07-12 close of $5.53 and puts the equity back to pricing VS-7375 near option value, which would say the market read the Q2 beat as a one-quarter launch artifact rather than the start of a self-funding commercial base. Three fundamental conditions would independently break the frame: the Oberland closing on 2026-08-28 failing to fund, which reopens the equity-issuance question the royalty deal was meant to close; the October 2026 update arriving with response rates in the ~20-patient cohorts that do not distinguish VS-7375 from competing oral KRAS G12D inhibitors; and co-pack net sales flatlining below the $25.1M Q2 level at the Q3 print, which would put the $40M quarterly bar for the contingent $25M tranche out of reach and shorten the runway math. Conversely, a clean October dataset plus continued sequential product-revenue growth would move the frame from binary-catalyst to a funded commercial-plus-pipeline story.

Correlation Notes

• Direct read-through from competing oral KRAS G12D programs — Revolution Medicines (RMC-9805), Astellas and BMS. A stronger PDAC dataset from any of them ahead of or alongside the October update compresses VSTM's differentiation regardless of its own numbers.
• Small-cap clinical-stage biotech beta: the name trades with XBI-type risk appetite and rate expectations, and a $136.4M cash balance against Phase 3 spend starting H1 2027 makes it sensitive to any shift in biotech financing conditions.
• Partial decoupling from pure-pipeline comps: with $25.1M of quarterly product revenue and a royalty financing secured against it, part of the equity now trades on launch-curve execution rather than binary trial risk alone.
• KRAS-franchise sentiment moves on conference calendars (ASCO, ESMO, AACR) more than on macro; abstract-title releases ahead of those meetings have historically moved this cohort before the data itself is public.